CL2008002709A1 - Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m - Google Patents

Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m

Info

Publication number
CL2008002709A1
CL2008002709A1 CL200802709A CL2008002709A CL2008002709A1 CL 2008002709 A1 CL2008002709 A1 CL 2008002709A1 CL 200802709 A CL200802709 A CL 200802709A CL 2008002709 A CL2008002709 A CL 2008002709A CL 2008002709 A1 CL2008002709 A1 CL 2008002709A1
Authority
CL
Chile
Prior art keywords
phosphopiruvate
deoxirribose
aldolasib
piruvato
dehydroxygenase
Prior art date
Application number
CL200802709A
Other languages
English (en)
Inventor
Mahesh Khan Muhammad Ayu Kumar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2008002709A1 publication Critical patent/CL2008002709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL200802709A 2007-09-11 2008-09-11 Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m CL2008002709A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99345607P 2007-09-11 2007-09-11

Publications (1)

Publication Number Publication Date
CL2008002709A1 true CL2008002709A1 (es) 2008-10-24

Family

ID=40019605

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200802709A CL2008002709A1 (es) 2007-09-11 2008-09-11 Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m

Country Status (16)

Country Link
US (2) US20090068231A1 (es)
EP (1) EP2209489A1 (es)
JP (1) JP2012501624A (es)
KR (1) KR20100072019A (es)
CN (1) CN101820902A (es)
AR (1) AR068419A1 (es)
AU (1) AU2008298749A1 (es)
BR (1) BRPI0816686A2 (es)
CA (1) CA2699367A1 (es)
CL (1) CL2008002709A1 (es)
CO (1) CO6270237A2 (es)
MX (1) MX2010002867A (es)
RU (1) RU2473682C2 (es)
TW (1) TW200920397A (es)
WO (1) WO2009036241A1 (es)
ZA (1) ZA201002515B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030619A2 (en) * 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
JP2012507537A (ja) 2008-10-31 2012-03-29 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド マイコプラズマ・ボビスの抗原を含む種々の抗原の多価ワクチン組成物における使用
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
CA2799732A1 (en) * 2010-05-19 2011-11-24 Bioproperties Pty Ltd Methods relating to an attenuated mycoplasma
SG10201708028VA (en) 2012-12-28 2017-10-30 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
CN104981252B (zh) 2012-12-28 2019-06-18 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
US9849168B2 (en) 2014-01-26 2017-12-26 Jiangsu Academy Of Agricultural Sciences Attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof
MX2018001841A (es) 2015-08-14 2018-08-01 Zoetis Services Llc Composiciones de mycoplasma bovis.
CN109476711B (zh) * 2016-08-09 2023-08-08 财团法人农业科技研究院 防治猪鼻霉浆菌感染的组合物及生产该组合物的方法
CN109234418B (zh) * 2018-11-20 2021-08-13 湖南中净生物科技有限公司 一种鉴别猪肺炎支原体野毒株和疫苗株的引物、试剂盒和方法
CN111172083A (zh) * 2020-03-06 2020-05-19 北京龙科方舟生物工程技术有限公司 一种用于高密度培养山羊支原体山羊肺炎亚种的培养基及其发酵培养方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307976B1 (en) * 1987-09-18 1993-06-23 Akzo Nobel N.V. Mycoplasma vaccine
US20020187162A1 (en) * 2001-04-21 2002-12-12 Geary Steven J. Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains

Also Published As

Publication number Publication date
CN101820902A (zh) 2010-09-01
US20090068231A1 (en) 2009-03-12
CA2699367A1 (en) 2009-03-19
AU2008298749A1 (en) 2009-03-19
MX2010002867A (es) 2010-05-24
EP2209489A1 (en) 2010-07-28
BRPI0816686A2 (pt) 2015-03-17
TW200920397A (en) 2009-05-16
KR20100072019A (ko) 2010-06-29
US20120045476A1 (en) 2012-02-23
RU2473682C2 (ru) 2013-01-27
ZA201002515B (en) 2010-12-29
AR068419A1 (es) 2009-11-18
CO6270237A2 (es) 2011-04-20
WO2009036241A1 (en) 2009-03-19
JP2012501624A (ja) 2012-01-26
RU2010110447A (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
CL2008002709A1 (es) Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m
DK3676316T3 (da) Flydende sammensætning omfattende biologiske enheder og anvendelser deraf
PE20150682A1 (es) Variantes de inmunoglobulinas y sus usos
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
CO6280406A2 (es) Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
CY1113770T1 (el) Κυκλικα αντι-μικροβιακα πεπτιδια
EA201171494A1 (ru) Миметики белка smac
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CO6801636A2 (es) Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteína e y sus usos
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BR112014014319A2 (pt) composições de cuidado oral
BRPI0916120A2 (pt) "composição de gel capilar transparente, e, sistema fixador capilar polimérico"
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
ITTO20110273A1 (it) Composizione di base per composizione cosmetica oppure farmaceutica.
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
CL2008000707A1 (es) Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
ITTO20060918A1 (it) Composizione cosmetica e farmaceutica e mezzo di coltura per la rigenerazione del tessuto cutaneo, e relativi usi
CL2017002733A1 (es) Adhesivos opacos en condición húmeda para aplicación de etiquetas
BR112018074874A2 (pt) composição cosmética antissinais, uso da composição, método de tratamento antissinais e dispositivo de aplicação
JP1735820S (ja) 香水瓶